GCM
PRME icon

Ghisallo Capital Management’s Prime Medicine PRME Stock Holding History

Ghisallo Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-70,000
Closed -$1.3M – 94
2022
Q4 		$1.3M Buy
+70,000
New +$1.26M 0.23% 86

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ghisallo Capital Management's PRME Position: Q1 2023 in Review

Ghisallo Capital Management sold out of Prime Medicine (PRME) in Q1 2023, closing a stake of 70,000 shares — an estimated $1.3M sold.

Ghisallo Capital Management first reported a position in PRME in Q4 2022 and held it in 1 quarter. The position peaked at $1.3M in Q4 2022. 76 funds tracked by Wall St. Rank hold PRME as of Q1 2023.

  • Ghisallo Capital Management reported no remaining Prime Medicine position as of Q1 2023 after selling out during the quarter.
  • Ghisallo Capital Management sold 70,000 Prime Medicine shares in Q1 2023, an estimated $1.3M.
  • Ghisallo Capital Management first reported a position in Prime Medicine in Q4 2022 and held it in 1 quarter.
  • Ghisallo Capital Management's Prime Medicine position peaked at $1.3M in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2023.

Based on Ghisallo Capital Management's 13F filing for Q1 2023, filed 15 May 2023.